Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 15/20 | 0.65 |
| ▸ | NMBR | P28336 | 2/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bombesin SCHEMBL29353003 | 0.94 | GRPR (0.70) | GRPRNMBR | |
| Bombesin SCHEMBL29364598 | 0.94 | GRPR (0.66) | GRPRNMBRRXFP1 | |
| SCHEMBL29475770 | 0.92 | GRPR (0.72) | GRPR | |
| SCHEMBL31738529 | 0.91 | GRPR (0.62) | GRPRNMBRRXFP1 | |
| SCHEMBL29565297 | 0.91 | GRPR (0.68) | GRPRNMBR | |
| SCHEMBL19372503 | 0.90 | GRPR (0.59) | GRPRNMBR | |
| SCHEMBL16360107 | 0.90 | GRPR (0.58) | GRPRNMBR | |
| SCHEMBL19365036 | 0.89 | GRPR (0.57) | GRPRNMBR | |
| SCHEMBL29851846 | 0.89 | GRPR (0.64) | GRPRNMBR | |
| SCHEMBL21186302 | 0.88 | GRPR (0.56) | GRPRNMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565506-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | Clarity Pharmaceuticals Ltd (AU) | 2026-03-03 | — | — | US | disclosed |
| US-20240190897-A1 | NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS | Clarity Pharmaceuticals Ltd (AU) | 2024-06-13 | — | — | US | disclosed |
| US-11905301-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | CLARITY PHARMACEUTICALS LTD. (AU) | 2024-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565506-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | CA12, CLTC, CA13 | GRPR 272/4885NMBR 517/4885RXFP1 149/4885 |
| US-11905301-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | NCL, NUDC, C3AR1 | GRPR 57/4885NMBR 8/4885RXFP1 1361/4885 |
| US-20240190897-A1 | NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS | NCL, NUDC, C3AR1 | GRPR 57/4885NMBR 8/4885RXFP1 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.